|
Weight-Loss Drug Qnexa Review Delayed By Late-Arriving REMS
The FDA is delaying its action goal date on Vivus’ obesity drug Qnexa to July 17 after the company’s late submission of a risk evaluation and mitigation strategy (REMS).
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives